# Cannabis, Beer, and Wellness: Meet Tilray Brands, Ireland’s Newest Publican – The Currency > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-beer-wellness-market-tilray-brands-ireland/ > **Published:** 2026-04-24T20:27:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:59:10-04:00 > **Clinical Summary:** Explore how Tilray Brands is shaping the cannabis beer wellness market in Ireland through pub acquisitions and product diversification. --- ✦ New CED Clinical Relevance #20 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. IndustryCBDTHCPolicy Clinical Summary Tilray Brands, a major cannabis producer, has expanded into Ireland’s beer and wellness market through acquisition of pub operations, representing a significant shift in how cannabis companies are diversifying their product portfolios and distribution channels. This move reflects the cannabis industry’s broader trend toward vertical integration and mainstream consumer positioning, particularly as regulatory environments evolve in European markets. For clinicians, this expansion underscores the growing commercialization of cannabis products outside traditional medical frameworks, which may influence patient expectations and self-medication behaviors around cannabis and cannabis-adjacent products. The blending of cannabis, alcohol, and wellness marketing in retail settings raises [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) considerations regarding product safety, drug interactions, and messaging to consumers who may view these products through a wellness rather than medical lens. Clinicians should be aware that patients may encounter an increasingly diverse array of cannabis-derived and cannabis-adjacent products in commercial settings, necessitating updated patient education about evidence-based uses versus marketed claims. The practical takeaway is that clinicians should proactively discuss patients’ cannabis and cannabis product use during intake, recognizing that commercial expansion is likely to increase access and normalization of these products outside clinical supervision. Clinical Perspective As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands globally, companies like Tilray Brands are entering traditional beverage markets, positioning cannabis products as wellness alternatives to alcohol. While this diversification reflects evolving regulatory landscapes and consumer preferences, clinicians should recognize that marketing cannabis as a “wellness” product does not address fundamental gaps in our understanding of long-term safety, dosing standardization, and potential interactions with medications or comorbid conditions. The comparison to alcohol itself warrants caution, since cannabis carries distinct pharmacological effects and population-specific risks including potential impacts on adolescent neurodevelopment, driving safety, and mental health in vulnerable individuals. Additionally, industry expansion often outpaces regulatory oversight and clinical evidence generation, creating a market-driven narrative that may not align with established therapeutic indications or [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) principles. Clinicians should remain vigilant in asking patients about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns and products, maintaining a non-judgmental stance while providing evidence-based counsel 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%3Cb%3ECannabis%3C%2Fb%3E%2C%20beer%2C%20and%20wellness%3A%20Meet%20Tilray%20Brands%2C%20Ireland%E2%80%99s%20newest%20publican%20%E2%80%93%20The%20Currency%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-beer-and-wellness-meet-tilray-brands-irelands-newest-publican-the-currency%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-beer-and-wellness-meet-tilray-brands-irelands-newest-publican-the-currency%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%3Cb%3ECannabis%3C%2Fb%3E%2C%20beer%2C%20and%20wellness%3A%20Meet%20Tilray%20Brands%2C%20Ireland%E2%80%99s%20newest%20publican%20%E2%80%93%20The%20Currency%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcannabis-beer-and-wellness-meet-tilray-brands-irelands-newest-publican-the-currency%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence 12 Best Alcohol Stocks to Buy Right Now – Insider Monkey Discover top alcohol stocks and how cannabis companies like Tilray are influencing the beverage market. Read More [Cannabis Tax Revenue Hits $28 Billion Since First Legalization](https://cedclinic.com/cannabis-tax-revenue-hits-28-billion-since-first-legalization/) Explore the financial impact of [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and market growth worldwide. [Learn More](https://cedclinic.com/cannabis-tax-revenue-hits-28-billion-since-first-legalization/) [TerrAscend (TSND) Is Quietly Rewriting US Cannabis Stocks – Ad-hoc-news.de](https://cedclinic.com/us-cannabis-industry-consolidation-terrascend-impact/) Insights into cannabis stock market trends and industry shifts relevant to Tilray’s expansion. [Explore Insights](https://cedclinic.com/us-cannabis-industry-consolidation-terrascend-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).